Tanya Parkinson

Medicine · Health Sciences

22h-index2.3kcitations43works3.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antifungal resistance and susceptibility(9), Hepatitis C virus research(9), Immune Response and Inflammation(6), Influenza Virus Research Studies(5), Research on Leishmaniasis Studies(5)

Publications43 total

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission
Science Advances·2024· 3 citedOpen Access
High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni
PLoS neglected tropical diseases·2016· 44 citedOpen Access
<scp><i>S</i></scp><i>taphylococcus aureus</i> haem biosynthesis: characterisation of the enzymes involved in final steps of the pathway
Molecular Microbiology·2015· 80 citedOpen Access
Drug Discovery for Human African Trypanosomiasis: Identification of Novel Scaffolds by the Newly Developed HTS SYBR Green Assay for Trypanosoma brucei
SLAS DISCOVERY·2014· 39 citedOpen Access
Repositioning: the fast track to new anti-malarial medicines?
Malaria Journal·2014· 44 citedOpen Access
Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen
Open Journal of Medicinal Chemistry·2013Open Access
Non-benzimidazole containing inhibitors of respiratory syncytial virus
Bioorganic & Medicinal Chemistry Letters·2012· 7 cited
Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs
PLoS neglected tropical diseases·2012· 93 citedOpen Access
An Integrated Transcriptomic and Meta-Analysis of Hepatoma Cells Reveals Factors That Influence Susceptibility to HCV Infection
PLoS ONE·2011· 21 citedOpen Access
Discovery of a highly potent series of TLR7 agonists
Bioorganic & Medicinal Chemistry Letters·2011· 20 citedOpen Access
Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads
PLoS neglected tropical diseases·2011· 33 citedOpen Access
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection
Bioorganic & Medicinal Chemistry Letters·2011· 27 citedOpen Access
The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection
MedChemComm·2010· 17 cited
Small Molecule Drug Discovery for Dengue and West Nile Viruses: Applying Experience from Hepatitis C Virus
Future Medicinal Chemistry·2010· 28 cited
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors
Journal of Hepatology·2010· 120 cited
The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A
Journal of Virological Methods·2010· 43 cited
Design and optimisation of potent gp120-CD4 inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 12 cited
Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction
Bioorganic & Medicinal Chemistry Letters·2009· 10 cited
The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication
Journal of Biological Chemistry·2009· 193 citedOpen Access
868 EVALUATION OF THE IMMUNOSTIMULATORY ACTIONS OF THE TLR7 AGONIST SM-360320 IN EX VIVO ASSAYS IN THE BLOOD OF HCV PATIENTS AND HEALTHY DONORS
Journal of Hepatology·2009Open Access
page 1 of 3Next →

Frequent Co-authors

David C. Pryde(8), Christopher A. Hitchcock(7), Carl Laxton(6), Thien-Duc Tran(6), Derek J. Falconer(5), Nigel Horscroft(5), Fiona M. Adam(5), Duncan A. Hay(5), Iain Gardner(5), Mark Gardner(4), A. K. Thomas(4), Frederick Calo(4), Donald S. Middleton(4), Manos Perros(4), Udayan Chatterji(3), Philippe Gallay(3), Paul Targett‐Adams(3), Peter Jones(3), Gerwyn Bish(3), Jonathan Duckworth(3)